Digest Network Come funziona
Network
/
Società
Ce
Non verificato

Centessa Pharmaceuticals plc

Di cosa scriviamo

FarmaceuticaFinanzaManagement/Organizzazione AziendaleMedicina Salute Benessere

12 comunicati stampa

Guarda tutti i comunicati
22/06/2026
Farmaceutica
Acquisition of Centessa by Lilly Approved by the High Court of Justice of England and Wales
Fonte
Centessa Pharmaceuticals plc
Emittente
GLOBENEWSWIRE
1.00
0
14/01/2026
Farmaceutica
Medicina Salute Benessere
Centessa Pharmaceuticals Announces Poster Presentation of New Preclinical Data Supporting Expansion of Orexin Receptor 2 (OX2R) Agonist Pipeline into Neuropsychiatric Indications at the 64th ACNP Annual Meeting
Fonte
Centessa Pharmaceuticals plc
Emittente
GLOBENEWSWIRE
1.00
0
11/12/2025
Farmaceutica
Centessa Pharmaceuticals Announces CEO Transition as Company Advances Strategy to Extend Orexin Leadership into Multiple Neuroscience Indications 
Fonte
Centessa Pharmaceuticals plc
Emittente
GLOBENEWSWIRE
1.00
0
11/11/2025
Farmaceutica
Finanza
Centessa Pharmaceuticals Announces Pricing of $250,000,000 Public Offering of American Depositary Shares
Fonte
Centessa Pharmaceuticals plc
Emittente
GLOBENEWSWIRE
1.00
0
11/11/2025
Farmaceutica
Finanza
Management/Organizzazione Aziendale
Centessa Pharmaceuticals Announces Proposed Public Offering of American Depositary Shares
Fonte
Centessa Pharmaceuticals plc
Emittente
GLOBENEWSWIRE
1.00
0
07/11/2025
Farmaceutica
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
Fonte
Centessa Pharmaceuticals plc
Emittente
GLOBENEWSWIRE
1.00
0
05/11/2025
Farmaceutica
Management/Organizzazione Aziendale
Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2025 and Provides Update on Potential Best-in-Class Orexin Receptor 2 (OX2R) Agonist Program
Fonte
Centessa Pharmaceuticals plc
Emittente
GLOBENEWSWIRE
1.00
0
12/08/2025
Farmaceutica
Management/Organizzazione Aziendale
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2025
Fonte
Centessa Pharmaceuticals plc
Emittente
GLOBENEWSWIRE
1.00
0
16/06/2025
Farmaceutica
Centessa Pharmaceuticals Announces Clearance of Investigational New Drug Application (IND) for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist; Clinical Data in Acutely Sleep-Deprived Healthy Volunteers Planned for this Year
Fonte
Centessa Pharmaceuticals plc
Emittente
GLOBENEWSWIRE
1.00
0
14/05/2025
Farmaceutica
Management/Organizzazione Aziendale
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2025
Fonte
Centessa Pharmaceuticals plc
Emittente
GLOBENEWSWIRE
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0